Clinical trials: Estrogen Receptor Positive Breast Cancer
Arthralgia, Breast Cancer
Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment
This randomized phase III trial studies testosterone to see how well it works compared to placebo in treating postmenopausal patients with arthralgia (joint pain) caused by anastrozole or letrozole.
- Conditions
- Arthralgia, Breast Cancer, Hot Flashes, Musculoskeletal Complications
- Trial name
- NCT01573442
- Testing
- testosterone
- Where
- 529 sites in United States, Puerto Rico
- Volunteers
- 227 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer
Phase I Study of the Combination of MLN9708 and Fulvestrant
Participants in this study will have been diagnosed with advanced breast cancer that has become worse while being treated with fulvestrant. Participants will have estrogen-receptor positive disease, and have completed menopause.
- Trial name
- Millennium (NCT02384746)
- Testing
- Fulvestrant, MLN9708
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Breast Cancer Stage II
Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer
This is an open-label, multicenter international trial in men and women with primary operable HR+/HER2-, ki67≥20%, grade 2 or 3 and stage II breast cancer to evaluate safety and long-term efficacy of a non-chemo treatment in…
- Trial name
- RIBOLARIS (NCT05296746)
- Testing
- Ribociclib (neoadjuvant), Chemotherapy (adjuvant), Ribociclib (adjuvant)
- Where
- 51 sites in France, Portugal and 1 more
- Volunteers
- 1,100 people
- Sponsor
- SOLTI Breast Cancer Research Group
Breast Cancer
Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer
A randomized multi-arm study evaluating the efficacy and safety of nivolumab versus placebo in combination with neoadjuvant (pre-surgery) chemotherapy and adjuvant (post-surgery) endocrine therapy in participants with high-risk…
- Trial name
- CheckMate 7FL (NCT04109066)
- Testing
- nivolumab, paclitaxel (PTX), anthracycline
- Where
- 240 sites in United States, Argentina and 30 more
- Volunteers
- 521 people
- Sponsor
- Bristol-Myers Squibb
Breast Cancer
Metformin and Simvastatin in Addition to Fulvestrant
This is a prospective single arm open-label Phase 2 study utilising the combination of Fulvestrant, Metformin and Simvastatin in post-menopausal ER-positive metastatic breast cancer, with the primary endpoint being Clinical…
- Trial name
- NCT03192293
- Testing
- Metformin/Simvastatin/Fulvestrant
- Where
- Singapore
- Volunteers
- 28 people
- Sponsor
- National University Hospital, Singapore
Metastatic Breast Cancer
Study Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up Period
PALBO is a Non-Interventional, National Study Of Real-World Evidence In Estrogen Receptor Positive, Her2 Negative Metastatic Breast Cancer Patients Treated With Palbociclib During A 2.5 Years Follow-Up Period.
- Trial name
- PALBO (NCT05135104)
- Testing
- Palbociclib
- Where
- 7 sites in Romania
- Volunteers
- 650 people
- Sponsor
- Asociatia Oncohelp - Centrul de Oncologie Oncohelp
Breast Cancer, Psychosocial Effects of Cancer and Its Treatment
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
RATIONALE: Studying how older women make treatment decisions and how these decisions affect the outcome of treatment may help doctors plan more effective treatments and improve patient quality of life.
- Trial name
- NCT00068328
- Testing
- psychosocial assessment and care, quality-of-life assessment
- Where
- 85 sites in United States
- Volunteers
- 1,706 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Early-stage Breast Cancer, Carbohydrate Engorgement
Breast Cancer Diet Intervention Study
The investigators have already proven that Mitotic Activity Index (MAI)is the most robust measure of proliferation in breast cancer tissue.
- Conditions
- Early-stage Breast Cancer, Carbohydrate Engorgement, Proliferation, Insulin Resistance
- Trial name
- BCDIS (NCT03886389)
- Testing
- PreOP
- Volunteers
- 80 people
- Sponsor
- Helse Stavanger HF
Breast Cancer
Lifestyle Intervention Study in Adjuvant Treatment of Early Breast Cancer
The primary objective of this trial is to evaluate the effect of the addition of a 2 year, centrally delivered individualized, telephone-based lifestyle intervention focusing on weight management to a mailed educational…
- Trial name
- LISA (NCT00463489)
- Testing
- Lifestyle intervention, Mail-based
- Where
- 21 sites in United States, Canada
- Volunteers
- 338 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
Breast Cancer
Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer
This study is to evaluate the efficacy of tucidinostat combined with exemestane as neoadjuvant strategy in estrogen receptor-positive early breast cancer patients and explore the genetic model which can predict neoadjuvant…
- Trial name
- NeoTEE (NCT04465097)
- Testing
- Tucidinostat, Exemestane, Ovarian function suppression
- Where
- China
- Volunteers
- 30 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Breast Cancer
Gut and Tumor Microbiome in Patients With Early Stage (II-III), Locally Advanced or Advanced ER-positive and HER2-negative Breast Cancer.
The purpose of this research study is to collect samples of blood and stool and analyse primary tumor from participants with breast cancer to see how the bacteria in the body affect cancer and how well it responds to treatment.
- Trial name
- NCT06126003
- Testing
- Observation
- Where
- 6 sites in United States
- Volunteers
- 2 people
- Sponsor
- BioCorteX Inc
Breast Cancer
Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer
Many patients with ER-positive or PR-positive breast cancer are treated with endocrine therapy. Although most ER/PR-positive tumors initially respond to hormonal therapy, patients often experience disease progression.
- Trial name
- NCT02291913
- Testing
- Everolimus, Exemestane, Tamoxifen
- Where
- 8 sites in United States
- Volunteers
- 48 people
- Sponsor
- SCRI Development Innovations, LLC
Breast Cancer
Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant
The purpose of this clinical trial is to study of the molecular features of postmenopausal women with hormone receptor-positive (HR+) HER2-negative advanced breast cancer on first-line treatment with ribociclib and letrozole and…
- Trial name
- BioItaLEE (NCT03439046)
- Testing
- Ribociclib, Letrozole, Alpelisib
- Where
- 41 sites in Italy
- Volunteers
- 287 people
- Sponsor
- Novartis Pharmaceuticals